Test Price
2,800 AED✅ Home Collection Available
AIMP1 Gene Leukodystrophy Hypomyelinating Type 3 Genetic Test – 2800 AED
Executive Summary & Core Metrics
This Next‑Generation Sequencing (NGS) test for the AIMP1 gene achieves 99.9% diagnostic sensitivity and is processed at our ISO 9001:2015 certified laboratory (Cert: INT/EGQ/2509DA/3139) under DHA Facility License 1143. The analysis is conducted in full compliance with Federal Decree‑Law No. 45 of 2021 on Personal Data Protection (PDPL) and Federal Law No. 2 of 2019 Concerning the Use of Information and Communication Technology in Health Fields. Patient consent and clinical safety adhere to Federal Decree‑Law No. 4 of 2016 on Medical Liability.
- ✓ Accuracy Guarantee: 99.9% Diagnostic Sensitivity via ISO 9001:2015 processing in a DHA‑licensed facility.
- ✓ Premium Logistics: VIP Mobile Phlebotomy & Temperature‑Controlled Cold‑Chain Home Collection (available daily 8 AM–11 PM) across all Emirates.
- ✓ Clinical Guidance: Complimentary telephonic post‑test clinical guidance with a certified genetic counsellor to interpret results.
- ✓ Insurance & Billing: Direct Billing Verification via WhatsApp +971 54 548 8731. All major UAE insurers accepted; minors require guardian consent per Federal Decree‑Law No. 4 of 2016.
Test Overview & Methodology
This test sequences the entire AIMP1 gene using Next‑Generation Sequencing (NGS) to diagnose Leukodystrophy, Hypomyelinating Type 3 (HLD3) – a rare autosomal recessive neurological disorder that disrupts myelin formation. The panel provides definitive genetic confirmation for symptomatic patients, carrier screening, and family planning.
Full gene coverage includes deep intronic regions, ensuring detection of both known and novel pathogenic variants. The NGS platform delivers a diagnostic yield exceeding 99% for this specific disorder.
| Feature | Our Test (AIMP1 NGS) | Closest Alternative (Single‑Gene Sanger) |
|---|---|---|
| Methodology | NGS, full gene coverage, deep intronic regions | Sanger sequencing of targeted exons only |
| Diagnostic Yield | >99% for known pathogenic variants | ~80% – misses deep intronic/novel variants |
| Turnaround Time | 3‑4 working weeks (cold‑chain verified) | 4‑8 weeks (may require multiple referrals) |
| Clinical Reporting | DHA‑aligned report with ICD‑10‑CM, LOINC, and genetic counselling note | Standard laboratory printout |
| Specimen Logistics | VIP home collection, ISO cold‑chain, WhatsApp tracking | Requires clinic visit, dry ice not guaranteed |
Physician Insight & Safety Protocols
"As a Consultant Medical Geneticist, I recognise the uncertainty that a suspected leukodystrophy diagnosis brings to families. This test is a powerful tool to confirm the exact AIMP1 mutation, but a negative result does not rule out all genetic leukodystrophies; clinical correlation and broader sequencing panels remain essential. I encourage families to reach out for a post‑test consultation to ensure the result is interpreted within the full context of clinical symptoms and developmental history."
— Lina Osama Zaki Quteineh, Consultant Medical Genetics, DHA 9294403
Safety Protocols & Medication Advisory
Medication Continuity
Do not discontinue prescribed medication without consulting your doctor. Inform the phlebotomist of all medications and supplements prior to sample collection.
Exclusion Criteria
- ⚠️ Acute febrile illness within 48 hours – postpone collection until symptom‑free.
- ⚠️ Active infection at venipuncture site – select alternate site or reschedule.
- ⚠️ Known bleeding diathesis – requires medical clearance from treating haematologist.
- ⚠️ Lack of signed informed consent – mandatory for all patients; for minors, consent must be provided by a legal guardian per Federal Decree‑Law No. 4 of 2016.
Emergency red flags: If the patient experiences rapid neurological deterioration, new‑onset seizures, or loss of consciousness, go directly to the nearest Emergency Department. Do not wait for test results.
Patient FAQ & Clinical Guidance
1. What is the AIMP1 gene test, and who should consider it?
The AIMP1 gene test uses next‑generation sequencing to detect mutations that cause hypomyelinating leukodystrophy type 3 (HLD3), a rare neurological disorder. It is recommended for children presenting with motor delay, muscle weakness, and neurological regression, as well as for carrier screening and family planning among at‑risk couples.
2. How is the sample collected, and is home service available across all Emirates?
A certified mobile phlebotomist collects a 2 mL peripheral whole blood sample in a dedicated DNA tube between 8 AM and 11 PM daily. Our temperature‑controlled cold‑chain logistics ensure sample integrity from any location in the UAE, including remote areas.
3. Will insurance cover this test, and what do I need to provide?
Most UAE insurers cover this genetic test when a neurologist or geneticist provides a referral letter and clinical notes. We verify insurance coverage directly via WhatsApp +971 54 548 8731. Please have your insurance card and physician referral ready.
UAE Regulatory & Data Privacy Adherence
Data Protection: This service complies with Federal Decree‑Law No. 45 of 2021 on Personal Data Protection (PDPL) and Federal Law No. 2 of 2019 Concerning the Use of Information and Communication Technology in Health Fields. All patient data are encrypted, access‑controlled, and used solely for clinical diagnostic purposes.
Clinical Safety & Consent: Clinical testing and patient consent procedures are governed by Federal Decree‑Law No. 4 of 2016 on Medical Liability. Our laboratory operates under DHA Facility License 1143 at: Premises 105, Floor 1, Building 33, Dubai Healthcare City, Dubai, UAE. Corporate lab branding: DNA Labs UAE.
Clinical & Logistical Metadata
| Test Name | AIMP1 Gene Leukodystrophy Hypomyelinating Type 3 Genetic Test |
| Price (AED) | 2,800 AED |
| Turnaround Time | 3–4 working weeks |
| Sample Type / Matrix | Peripheral Whole Blood (2 mL) – VIP Mobile Phlebotomy & Temperature‑Controlled Cold‑Chain Home Collection (available daily 8 AM–11 PM) |
| Methodology Used | Next‑Generation Sequencing (NGS), full gene coverage including deep intronic regions |
| ICD‑10‑CM Code | G37.8 |
| LOINC Code | 88866-1 |
| DHA Facility License & Laboratory Address | DHA License 1143 | Premises 105, Floor 1, Building 33, Dubai Healthcare City, Dubai, UAE | DNA Labs UAE |
دعم ثنائي اللغة متاح
التحقق من التغطية التأمينية
Check Insurance Coverage Instantly
Stop the guesswork. Send a photo of your Insurance Card and Doctor's Prescription to our DHA-Certified Verification Team on WhatsApp.
توقف عن التخمين. أرسل صورة من بطاقة التأمين ووصفة الطبيب إلى فريق التحقق المعتمد من هيئة الصحة بدبي عبر الواتساب. احصل على تحديث الحالة في دقائق.
Available in Arabic, English, Hindi & Urdu
ISMS 27001:2022
ISO Accredited
HIPAA
All reports reviewed by DHA-Certified physicians